Oculis' OCS-01 Drug Fails Phase 3 Trial for Diabetic Macular Edema; FDA Filing Halted
OCS sits 42% above its 52-week low of $16 on elevated volume (3.8× avg).
Summary
Oculis' OCS-01 drug failed to meet its primary endpoint in Phase 3 DIAMOND trials for Diabetic Macular Edema (DME), leading the company to abandon plans for an FDA filing for this indication. This is a significant setback for a key pipeline asset, removing a major potential revenue driver. The news follows several positive updates regarding the company's strong cash position and progress on other drug candidates, such as the EMA PRIME designation for Privosegtor and an FDA SPA for PIONEER-1. While a secondary endpoint showed retinal thickness reduction, the primary failure is a material blow to the company's valuation and future prospects in the DME market.
At the time of this announcement, OCS was trading at $22.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $16.00 to $34.48. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.